My ePortfolio Register   

AACR 2014 /
New antibody-drug conjugate shows early promise against all forms of melanoma

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1812

Dr Jeffrey Infante - Tennessee Oncology, Nashville, USA

Dr Infante talks to ecancertv at the AACR conference about the latest addition to a class of antibody drug conjugates, DEDN6525A, and the positive role it may play in fighting melanoma.

The phase I clinical trial suggested that it was safe, tolerable, and showed hints of activity against different forms of melanoma.

Read the article for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence